Immunovant, Inc.
No enriched coverage for $IMVT in the last 7 days.
Immunovant, Inc. (IMVT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 2, 2026, Immunovant, Inc. ( “ Immunovant ” ) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ” ). There were 198,373,370 shares of common stock and Series A preferred stock represented
Gloria Melanie (Chief Operating Officer) sold 3,056 shares of Immunovant, Inc. (IMVT) at $44.16 ($0.13M total) on 2026-08-20.
Immunovant (IMVT) reported wider Q1 2026 net loss of $153.22M, or $0.75/share, versus $120.61M, or $0.71/share a year earlier. The company cited upcoming pivotal data readouts and potential launches, alongside cash inflows tied to a Moderna settlement. The article also references analyst projections for 2029 revenue and earnings.
Recent IMVT coverage spans insider activity, corporate actions and financial news.
In the last 30 days, IMVT insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($200K). The most active reporter was Pande Atul with 1 filing. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.
This is a corporate governance update with no new operating or financial guidance, so near-term price impact is likely limited.
Minor dilution of insider ownership may slightly pressure the stock.
Near-term sentiment is likely driven by the next IMVT-1402 pivotal readouts, while the wider loss and potential dilution keep downside risk elevated.
The filing updates cash runway and R&D burn while reiterating IMVT-1402 development timing, which can shift biotech risk appetite and near-term valuation expectations.
Routine insider open-market sale by the CFO, with no 10b5-1 plan cited, may slightly affect near-term sentiment but is not a fundamental catalyst.
AlphAI scores every news story that mentions IMVT with an AI model for sentiment and relevance, and aggregates insider trades from Immunovant, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Immunovant, Inc. (IMVT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 2, 2026, Immunovant, Inc. ( “ Immunovant ” ) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ” ). There were 198,373,370 shares of common stock and Series A preferred stock represented
3 min readGloria Melanie (Chief Operating Officer) sold 3,056 shares of Immunovant, Inc. (IMVT) at $44.16 ($0.13M total) on 2026-08-20.
1 min readImmunovant (IMVT) reported wider Q1 2026 net loss of $153.22M, or $0.75/share, versus $120.61M, or $0.71/share a year earlier. The company cited upcoming pivotal data readouts and potential launches, alongside cash inflows tied to a Moderna settlement. The article also references analyst projections for 2029 revenue and earnings.
5 min readImmunovant, Inc. (IMVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 • All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory dem
4 min readGirao Tiago (Chief Financial Officer) sold 6,798 shares of Immunovant, Inc. (IMVT) at $38.69 ($0.26M total) on 2026-07-23.
2 min readStout Jay S (Chief Technology Officer) sold 2,857 shares of Immunovant, Inc. (IMVT) at $38.69 ($0.11M total) on 2026-07-23.
1 min readStout Jay S (Chief Technology Officer) sold 3,487 shares of Immunovant, Inc. (IMVT) at an average of $39.55 ($39.53–$39.99, $0.14M total) across 4 trades on 2026-07-08.
1 min readVenker Eric (Chief Executive Officer) sold 3,092 shares of Immunovant, Inc. (IMVT) at $38.48 ($0.12M total) on 2026-07-02.
1 min readVenker Eric (Chief Executive Officer) sold (to issuer) 86,629 shares of Immunovant, Inc. (IMVT) at $38.14 ($3.30M total) on 2026-07-01.
1 min readGloria Melanie (Chief Operating Officer) sold 17,714 shares of Immunovant, Inc. (IMVT) at an average of $38.31 ($38.18–$38.95, $0.68M total) across 2 trades on 2026-06-26.
3 min read